Johnson & Johnson (NYSE: JNJ) Shuns $100 Billion GLP-1 Race, Positioning Itself As A Stronger Long-Term Bet Than Eli Lilly (NYSE: LLY)
From the article
Johnson & Johnson (NYSE: JNJ) is deliberately stepping back from the GLP-1 weight-loss drug market, a sector widely valued at over $100 billion. CEO Joaquin Duato has made clear he has no intention of chasing the weight-loss drug trend, preferring instead to focus on oncology and the company’s sprawling medical device business. The decision stands […] The post Johnson & Johnson (NYSE: JNJ) Shuns $100 Billion GLP-1 Race, Positioning Itself As A Stronger Long-Term Bet Than Eli Lilly (NYSE: LLY) appeared first on Foreign Policy Journal .
Continue reading on Foreign Policy JournalYou might also wanna read
The European Digital Power of Attorney: The Mountain in Labour? Or How the EU Cannot Do a Cost-Benefit Analysis Even If Europe’s Survival Depended on It
blogs.law.ox.ac.uk·just now
New Zealand Proposes Bill to Restrict Climate Change Lawsuits Against Emitters
New Zealand has proposed legislation to limit climate change litigation, preventing individuals from suing high greenhouse gas emitters over
forbes.com·11m ago
Analyse von Trumps Rhetorik und Medientaktik beim NATO-Gipfel
The article analyzes Donald Trump's rhetorical tactics and media manipulation strategies, particularly during the NATO summit. It discusses
kurier.at·17m ago
Burnham calls for ‘more open’ public debate about defence spending – UK politics live
The Guardian·22m ago
Stubb pushes for a stronger European Nato
NordiskPost·23m ago
Informationen zum Mpox-Virus
bundesgesundheitsministerium.de·27m ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.